NCT04115410: PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study |
|
|
| Unknown status | N/A | 4724 | NA | PD-1 inhibitor, OPDIVO, KEYTRUDA, TECENTRIQ, Chemotherapy Drugs, Cancer, Carboplatin, Cisplatin, Vinorelbine, Gemcitabine, Pemetrexed, Docetaxel, Vinblastine, Mitomycin C, Gefitinib, Erlotinib, Afatinib, Crizotinib, Ceritinib, Alectinib, Osimertinib | Sungkyunkwan University, Ministry of Food and Drug Safety, Korea | Carcinoma, Non-Small-Cell Lung, Immune-Related Adverse Events | 09/21 | 12/21 | | |
